NASDAQ:MYOK - MyoKardia Stock Price, Price Target & More

$49.60 +0.80 (+1.64 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$48.80
Today's Range$48.30 - $49.95
52-Week Range$12.10 - $62.83
Volume134,349 shs
Average Volume404,847 shs
Market Capitalization$1.80 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.64

About MyoKardia (NASDAQ:MYOK)

MyoKardia logoMyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900

Debt

Debt-to-Equity RatioN/A
Current Ratio6.35%
Quick Ratio6.35%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.50 million
Price / Sales79.23
Cash FlowN/A
Price / CashN/A
Book Value$6.76 per share
Price / Book7.34

Profitability

EPS (Most Recent Fiscal Year)($1.40)
Net Income$-45,950,000.00
Net Margins-204.48%
Return on Equity-24.58%
Return on Assets-19.88%

Miscellaneous

Employees102
Outstanding Shares35,940,000

How to Become a New Pot Stock Millionaire

MyoKardia (NASDAQ:MYOK) Frequently Asked Questions

What is MyoKardia's stock symbol?

MyoKardia trades on the NASDAQ under the ticker symbol "MYOK."

How were MyoKardia's earnings last quarter?

MyoKardia (NASDAQ:MYOK) announced its quarterly earnings results on Thursday, March, 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.20. The biotechnology company earned $5.60 million during the quarter, compared to the consensus estimate of $5.63 million. MyoKardia had a negative return on equity of 24.58% and a negative net margin of 204.48%. View MyoKardia's Earnings History.

What price target have analysts set for MYOK?

6 brokers have issued twelve-month target prices for MyoKardia's shares. Their predictions range from $54.00 to $83.00. On average, they expect MyoKardia's share price to reach $66.6667 in the next twelve months. View Analyst Ratings for MyoKardia.

Who are some of MyoKardia's key competitors?

Who are MyoKardia's key executives?

MyoKardia's management team includes the folowing people:
  • Tassos Anastasios Gianakakos, President, Chief Executive Officer, Director (Age 44)
  • June Lee M.D., Chief Operating Officer (Age 51)
  • Jake Bauer, Senior Vice President - Finance and Corporate Development (Age 38)
  • Joseph Lee Lambing Ph.D., Senior Vice President - Nonclinical and Pharmaceutical Development (Age 54)
  • Robert Scott McDowell Ph.D., Senior Vice President - Drug Discovery (Age 59)
  • Marc Semigran M.D., Chief Medical Officer (Age 60)
  • Mark L. Perry J.D., Interim Non-Executive Chairman of the Board, Lead Independent Director (Age 61)
  • Sunil Agarwal M.D., Independent Director (Age 47)
  • Mary B. Cranston, Independent Director (Age 69)
  • David P. Meeker M.D., Independent Director (Age 63)

Has MyoKardia been receiving favorable news coverage?

Headlines about MYOK stock have been trending somewhat positive on Friday, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MyoKardia earned a media sentiment score of 0.11 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.64 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of MyoKardia?

Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MyoKardia's stock price today?

One share of MYOK stock can currently be purchased for approximately $49.60.

How big of a company is MyoKardia?

MyoKardia has a market capitalization of $1.80 billion and generates $22.50 million in revenue each year. The biotechnology company earns $-45,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. MyoKardia employs 102 workers across the globe.

How can I contact MyoKardia?

MyoKardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]


MarketBeat Community Rating for MyoKardia (MYOK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about MyoKardia and other stocks. Vote "Outperform" if you believe MYOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MyoKardia (NASDAQ:MYOK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for MyoKardia in the last 12 months. Their average twelve-month price target is $66.6667, suggesting that the stock has a possible upside of 34.41%. The high price target for MYOK is $83.00 and the low price target for MYOK is $54.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $66.6667$63.00$55.6667$55.00
Price Target Upside: 34.41% upside18.15% upside5.83% upside13.75% upside

MyoKardia (NASDAQ:MYOK) Consensus Price Target History

Price Target History for MyoKardia (NASDAQ:MYOK)

MyoKardia (NASDAQ:MYOK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Wells FargoReiterated RatingOutperform$70.00MediumView Rating Details
3/9/2018CowenReiterated RatingBuy$56.00LowView Rating Details
3/9/2018BMO Capital MarketsBoost Price TargetOutperform -> Outperform$65.00 -> $83.00HighView Rating Details
3/9/2018Credit Suisse GroupBoost Price TargetOutperform -> Outperform$60.00 -> $68.00HighView Rating Details
3/9/2018WedbushBoost Price TargetOutperform$51.00 -> $69.00HighView Rating Details
12/12/2017JPMorgan ChaseInitiated CoverageOverweight -> Overweight$54.00MediumView Rating Details
(Data available from 4/20/2016 forward)

Earnings

MyoKardia (NASDAQ:MYOK) Earnings History and Estimates Chart

Earnings by Quarter for MyoKardia (NASDAQ:MYOK)

MyoKardia (NASDAQ:MYOK) Earnings Estimates

2018 EPS Consensus Estimate: ($1.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.41)($0.41)($0.41)
Q2 20181($0.43)($0.43)($0.43)
Q3 20181($0.44)($0.44)($0.44)
Q4 20181($0.46)($0.46)($0.46)

MyoKardia (NASDAQ MYOK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018Q4 2017($0.41)($0.21)$5.63 million$5.60 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.42)($0.42)$6.10 million$5.63 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.37)($0.41)$6.73 million$5.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.36)($0.37)$7.00 million$5.60 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.18)$0.44$3.55 million$28.60 millionViewN/AView Earnings Details
11/7/2016Q316($0.07)($0.35)$4.83 million$3.55 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.37)$3.55 million$3.55 millionViewN/AView Earnings Details
5/12/2016Q1($0.53)($0.32)$3.55 million$3.55 millionViewN/AView Earnings Details
3/18/2016Q4($0.68)($0.48)$3.55 million$3.55 millionViewN/AView Earnings Details
11/18/2015Q3 2015($2.78)$3.55 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

MyoKardia (NASDAQ:MYOK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MyoKardia (NASDAQ MYOK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.40%
Institutional Ownership Percentage: 83.49%
Insider Trading History for MyoKardia (NASDAQ:MYOK)
Institutional Ownership by Quarter for MyoKardia (NASDAQ:MYOK)

MyoKardia (NASDAQ MYOK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/11/2018Jake BauerInsiderSell5,000$50.00$250,000.0066,777View SEC Filing  
4/4/2018Anastasios GianakakosInsiderSell3,000$47.95$143,850.0077,390View SEC Filing  
3/26/2018Jake BauerInsiderSell164$50.95$8,355.8061,941View SEC Filing  
3/5/2018Anastasios GianakakosInsiderSell3,000$61.07$183,210.0077,390View SEC Filing  
2/26/2018Anastasios GianakakosInsiderSell5,000$60.00$300,000.0079,390View SEC Filing  
2/5/2018Anastasios GianakakosInsiderSell3,000$51.05$153,150.0077,390View SEC Filing  
1/12/2018Joseph LambingInsiderSell5,000$50.00$250,000.0095,846View SEC Filing  
1/9/2018Jake BauerInsiderSell5,000$45.00$225,000.0056,777View SEC Filing  
1/4/2018Anastasios GianakakosInsiderSell3,000$41.70$125,100.00512,117View SEC Filing  
1/3/2018Kevin P StarrDirectorSell816,326$42.00$34,285,692.00View SEC Filing  
1/2/2018Jake BauerInsiderSell5,000$42.89$214,450.0062,877View SEC Filing  
12/21/2017Anastasios GianakakosInsiderSell3,000$41.09$123,270.00512,117View SEC Filing  
11/6/2017Anastasios GianakakosCEOSell4,300$40.23$172,989.00513,417View SEC Filing  
10/4/2017Anastasios GianakakosInsiderSell4,300$40.86$175,698.00View SEC Filing  
10/3/2017Kevin P StarrDirectorSell75,313$40.28$3,033,607.64View SEC Filing  
9/26/2017Kevin P StarrDirectorSell601,400$43.00$25,860,200.00View SEC Filing  
9/26/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell400,000$43.00$17,200,000.00View SEC Filing  
9/25/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell201,400$43.00$8,660,200.00View SEC Filing  
9/11/2017Rock Ventures Ii L.P. ThirdMajor ShareholderSell221,250$41.30$9,137,625.00View SEC Filing  
9/8/2017Kevin P StarrDirectorSell201,250$41.01$8,253,262.50View SEC Filing  
9/5/2017Anastasios GianakakosInsiderSell4,300$43.02$184,986.00512,463View SEC Filing  
8/22/2017Joseph LambingInsiderSell5,000$45.00$225,000.0099,718View SEC Filing  
8/15/2017Joseph LambingInsiderSell5,000$40.00$200,000.00104,718View SEC Filing  
8/14/2017SanofiMajor ShareholderBuy350,000$35.50$12,425,000.00View SEC Filing  
8/14/2017Wendy L YarnoDirectorBuy1,408$35.50$49,984.001,408View SEC Filing  
8/8/2017Joseph LambingInsiderSell15,000$30.00$450,000.00119,718View SEC Filing  
8/7/2017Jake BauerInsiderSell15,000$28.33$424,950.0075,545View SEC Filing  
8/4/2017Anastasios GianakakosCEOSell4,300$16.62$71,466.00512,463View SEC Filing  
7/25/2017Anastasios GianakakosInsiderSell32,988$15.00$494,820.00541,151View SEC Filing  
3/20/2017Anastasios GianakakosCEOSell1,412$15.00$21,180.00509,454View SEC Filing  
3/20/2017Jake BauerInsiderSell667$15.00$10,005.0083,900View SEC Filing  
10/3/2016SanofiMajor ShareholderBuy450,000$15.00$6,750,000.00View SEC Filing  
11/3/2015Anastasios GianakakosCEOBuy1,350$10.00$13,500.00482,165View SEC Filing  
11/3/2015Jonathan C FoxInsiderBuy3,000$10.00$30,000.00239,190View SEC Filing  
11/3/2015Mark L PerryDirectorBuy5,000$10.00$50,000.0025,408View SEC Filing  
11/3/2015SanofiMajor ShareholderBuy900,000$10.00$9,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MyoKardia (NASDAQ MYOK) News Headlines

Source:
DateHeadline
MyoKardia (MYOK) Receives Consensus Recommendation of "Buy" from BrokeragesMyoKardia (MYOK) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 19 at 5:40 PM
$7.82 Million in Sales Expected for MyoKardia (MYOK) This Quarter$7.82 Million in Sales Expected for MyoKardia (MYOK) This Quarter
www.americanbankingnews.com - April 18 at 3:56 AM
-$0.28 Earnings Per Share Expected for MyoKardia (MYOK) This Quarter-$0.28 Earnings Per Share Expected for MyoKardia (MYOK) This Quarter
www.americanbankingnews.com - April 16 at 9:21 AM
Wells Fargo Reiterates "Outperform" Rating for MyoKardia (MYOK)Wells Fargo Reiterates "Outperform" Rating for MyoKardia (MYOK)
www.americanbankingnews.com - April 13 at 10:37 AM
Jake Bauer Sells 5,000 Shares of MyoKardia (MYOK) StockJake Bauer Sells 5,000 Shares of MyoKardia (MYOK) Stock
www.americanbankingnews.com - April 12 at 10:10 PM
BMO Capital Markets Reiterates Buy Rating for MyoKardia (MYOK)BMO Capital Markets Reiterates Buy Rating for MyoKardia (MYOK)
www.americanbankingnews.com - April 12 at 5:09 PM
Myokardia (MYOK) Upgraded by Zacks Investment Research to "Hold"Myokardia (MYOK) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 7 at 12:39 AM
Insider Selling: Myokardia Inc (MYOK) Insider Sells 3,000 Shares of StockInsider Selling: Myokardia Inc (MYOK) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - April 5 at 10:20 PM
MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial OfficerMyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer
finance.yahoo.com - April 4 at 8:51 AM
MyoKardia commences mid-stage study of mavacantem in non-obstructive HCMMyoKardia commences mid-stage study of mavacantem in non-obstructive HCM
seekingalpha.com - April 2 at 5:03 PM
MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy PatientsMyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients
finance.yahoo.com - April 2 at 5:03 PM
Edited Transcript of MYOK earnings conference call or presentation 8-Mar-18 9:30pm GMTEdited Transcript of MYOK earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - April 1 at 8:49 AM
 Brokerages Expect Myokardia Inc (MYOK) Will Announce Quarterly Sales of $7.82 Million Brokerages Expect Myokardia Inc (MYOK) Will Announce Quarterly Sales of $7.82 Million
www.americanbankingnews.com - April 1 at 4:02 AM
Myokardia (MYOK) Downgraded by Zacks Investment ResearchMyokardia (MYOK) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:28 PM
 Analysts Expect Myokardia Inc (MYOK) Will Post Earnings of -$0.28 Per Share Analysts Expect Myokardia Inc (MYOK) Will Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - March 30 at 1:21 PM
Myokardia (MYOK) Stock Rating Upgraded by BidaskClubMyokardia (MYOK) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 26 at 8:56 AM
Myokardia Inc (MYOK) Receives Average Recommendation of "Buy" from BrokeragesMyokardia Inc (MYOK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 25 at 5:30 PM
Myokardia (MYOK) Downgraded by BidaskClubMyokardia (MYOK) Downgraded by BidaskClub
www.americanbankingnews.com - March 24 at 1:18 PM
Myokardia (MYOK) Upgraded by Zacks Investment Research to "Buy"Myokardia (MYOK) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 18 at 2:18 PM
Myokardia (MYOK) Downgraded to Hold at Zacks Investment ResearchMyokardia (MYOK) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 18 at 12:20 AM
$7.82 Million in Sales Expected for Myokardia Inc (MYOK) This Quarter$7.82 Million in Sales Expected for Myokardia Inc (MYOK) This Quarter
www.americanbankingnews.com - March 15 at 5:42 AM
Myokardia Inc Forecasted to Earn FY2022 Earnings of $11.57 Per Share (MYOK)Myokardia Inc Forecasted to Earn FY2022 Earnings of $11.57 Per Share (MYOK)
www.americanbankingnews.com - March 12 at 10:02 AM
Myokardia (MYOK) Downgraded by BidaskClub to "Hold"Myokardia (MYOK) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - March 10 at 5:28 PM
Myokardia (MYOK) PT Raised to $69.00Myokardia (MYOK) PT Raised to $69.00
www.americanbankingnews.com - March 9 at 10:54 PM
BMO Capital Markets Boosts Myokardia (MYOK) Price Target to $83.00BMO Capital Markets Boosts Myokardia (MYOK) Price Target to $83.00
www.americanbankingnews.com - March 9 at 8:23 PM
Myokardias (MYOK) "Buy" Rating Reaffirmed at CowenMyokardia's (MYOK) "Buy" Rating Reaffirmed at Cowen
www.americanbankingnews.com - March 9 at 4:55 PM
Myokardia (MYOK) Releases Quarterly  Earnings Results, Beats Estimates By $0.20 EPSMyokardia (MYOK) Releases Quarterly Earnings Results, Beats Estimates By $0.20 EPS
www.americanbankingnews.com - March 9 at 4:27 PM
Credit Suisse Group Raises Myokardia (MYOK) Price Target to $68.00Credit Suisse Group Raises Myokardia (MYOK) Price Target to $68.00
www.americanbankingnews.com - March 9 at 4:25 PM
BRIEF-Myokardia Files For Potential Mixed Shelf OfferingBRIEF-Myokardia Files For Potential Mixed Shelf Offering
www.reuters.com - March 9 at 9:05 AM
MyoKardia (MYOK) Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in oHCMMyoKardia (MYOK) Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in oHCM
www.streetinsider.com - March 9 at 9:05 AM
MyoKardia, Inc. to Host Earnings CallMyoKardia, Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 6:06 PM
Earnings Preview For MyoKardiaEarnings Preview For MyoKardia
finance.yahoo.com - March 8 at 6:06 PM
MyoKardia Reports Fourth Quarter and Full Year 2017 Financial ResultsMyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 6:06 PM
MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy PatientsMyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
finance.yahoo.com - March 8 at 6:06 PM
Myokardia Sees Unusually High Options Volume (MYOK)Myokardia Sees Unusually High Options Volume (MYOK)
www.americanbankingnews.com - March 8 at 8:14 AM
Myokardia Inc (MYOK) Insider Sells $183,210.00 in StockMyokardia Inc (MYOK) Insider Sells $183,210.00 in Stock
www.americanbankingnews.com - March 7 at 7:12 PM
MyoKardia to Present at the Cowen and Company 38th Annual Health Care ConferenceMyoKardia to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:44 AM
Myokardia (MYOK) Set to Announce Earnings on MondayMyokardia (MYOK) Set to Announce Earnings on Monday
www.americanbankingnews.com - March 5 at 2:34 AM
Myokardia Inc (MYOK) Holdings Lowered by EAM Investors LLCMyokardia Inc (MYOK) Holdings Lowered by EAM Investors LLC
www.americanbankingnews.com - March 2 at 1:06 PM
Hudson Bay Capital Management LP Takes Position in Myokardia Inc (MYOK)Hudson Bay Capital Management LP Takes Position in Myokardia Inc (MYOK)
www.americanbankingnews.com - March 2 at 12:57 PM
MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018
finance.yahoo.com - March 1 at 5:26 PM
Myokardia Inc (MYOK) Insider Sells $300,000.00 in StockMyokardia Inc (MYOK) Insider Sells $300,000.00 in Stock
www.americanbankingnews.com - March 1 at 12:38 AM
Myokardia Inc (MYOK) Given Consensus Rating of "Buy" by AnalystsMyokardia Inc (MYOK) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 28 at 5:32 PM
147,408 Shares in Myokardia Inc (MYOK) Acquired by Trustees of Princeton University147,408 Shares in Myokardia Inc (MYOK) Acquired by Trustees of Princeton University
www.americanbankingnews.com - February 27 at 2:17 PM
Today’s Research Reports on Stocks to Watch: Endocyte and MyoKardiaToday’s Research Reports on Stocks to Watch: Endocyte and MyoKardia
finance.yahoo.com - February 27 at 8:50 AM
Citadel Advisors LLC Has $2.55 Million Position in Myokardia Inc (MYOK)Citadel Advisors LLC Has $2.55 Million Position in Myokardia Inc (MYOK)
www.americanbankingnews.com - February 26 at 1:32 PM
Zacks: Brokerages Anticipate Myokardia Inc (MYOK) Will Post Quarterly Sales of $5.63 MillionZacks: Brokerages Anticipate Myokardia Inc (MYOK) Will Post Quarterly Sales of $5.63 Million
www.americanbankingnews.com - February 26 at 8:56 AM
Myokardia (MYOK) Rating Increased to Buy at BidaskClubMyokardia (MYOK) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - February 17 at 1:24 PM
BRIEF-Myokardia Begins Patient Dosing In Phase 1B Clinical Study Of Myk-491BRIEF-Myokardia Begins Patient Dosing In Phase 1B Clinical Study Of Myk-491
www.reuters.com - February 15 at 8:13 AM
MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare ConferenceMyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference
finance.yahoo.com - February 14 at 5:11 PM

SEC Filings

MyoKardia (NASDAQ:MYOK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MyoKardia (NASDAQ:MYOK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MyoKardia (NASDAQ MYOK) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.